Davunetide (NAP)_Dosage, benefits & legal status
Also known as NAP, NAPVSIPQ, CP201, AL-108
An eight amino acid brain peptide that reached large human trials and failed the main one.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is Davunetide (NAP)?
Plain language first. The technical label stays, but it never stands alone.Overview
A brain peptide that got as far as large human trials and did not work in the disease it was tested in. Which is more than most compounds here can say in either direction.
NAPVSIPQ, an octapeptide fragment of activity-dependent neuroprotective protein (ADNP). Microtubule-stabilising via recruitment of tau and end-binding proteins; activity is tau-dependent. Preferential interaction with 3R over 4R tau isoforms. Failed to meet primary endpoints in a Phase 2/3 progressive supranuclear palsy trial, a 4R tauopathy, after an efficacy signal in prodromal Alzheimer's disease, a mixed 3R/4R tauopathy.
What it's used for
Studied for tauopathies, a group of brain diseases involving the tau protein. Sold online for cognition and neuroprotection.
How does Davunetide (NAP) work?
What it does in the body, and where.Neurons move cargo along internal tracks, and tau is what keeps those tracks stable.
- 01It stabilises microtubulesNAP is reported to recruit tau and end-binding proteins to microtubules, preventing their breakdown. Its activity requires tau to be present at all.
- 02It reaches the cell nucleusLater work found NAP distributing into the nucleus as well as the cytoplasm, which the authors offer as an explanation for its range of reported effects.
- 03It prefers one form of tau over anotherAffinity work found NAP interacting preferentially with the 3-repeat form of tau rather than the 4-repeat form, which is offered as an explanation for why it worked in one disease and not another.
What else is it used for?
Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
- Progressive supranuclear palsy, where a Phase 2/3 trial did not meet its endpointsInvestigational
- Early Alzheimer's disease, where an earlier trial reported a signalInvestigational
- Schizophrenia-related cognitive impairmentInvestigational
- ADNP syndrome, a rare genetic conditionInvestigational
The published record
Papers and trials about Davunetide (NAP)
91 papers tagged human · 42 not reviews or lab · 9 clinical trial publications
5 registered trials · 1 with posted results
Furthest stage reached: Phase 2, results posted
Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count.
At a glance
Four things to know about Davunetide (NAP)
Evidence
Investigational
Category
Brain, mood and sleep
Common vial
5 mg
Half-life
Nothing published in humans
How much, and do you cycle it?
The range, and whether you take breaks.30 mg per dose, twice daily in the trial. No established pattern No range
No published human study establishes a schedule.
Nothing published in humansNo figure
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Choose your mix
Measuring the water1 mL = one full 100-unit syringe.
How do you store it?
Before mixing, and after.Fridge after opening. Use within about 30 days.
Store sealed Davunetide (NAP) in the fridge. Once opened, keep it upright in the fridge and plan to finish it inside roughly 30 days. Keep it out of light and do not freeze the liquid.
What are the side effects and cautions?
Known cautions and warnings for this compound.Solubility, computed: 25% charged residues, 62% hydrophobic. Water usually sufficient.
A first-pass rule from peptide manufacturers' guidance. It does not account for disulfide bridges, salt form or how the powder was dried, and it predicts what should be easy rather than what will happen in your vial.
Who should avoid it
- Pregnancy or breastfeeding
- Any use outside a trial, since the largest trial did not show benefit
Stop and get help
- Any allergic reaction
- Any new neurological symptom
Common effects
- Was generally well tolerated in the trials that ran.
- Efficacy, not safety, is where it failed.
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is Davunetide (NAP) approved?
And where the numbers on this page come from.No. Davunetide (NAP) is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteNasal spray, or injected under the skin
- Checked20 September 2026
- DoseFrom published clinical trials. Not approved by a regulator for this dose.
- Vial sizeFrom what vendors typically list; not a recommendation.
- SourcesNone traced yet.
What has happened recently
We have not yet written a full regulatory note for this compound. The status above is current as of the date shown.
You can compare this against the whole library, or read how to check a seller.
What else is like Davunetide (NAP)?
Others in Brain, mood and sleep, side by side.If you're weighing Davunetide (NAP), it's worth reading Dermorphin, GB-115, and P7C3 in the same class.
An eight amino acid brain peptide that reached large human trials and failed the main one.
- Dose
- 30 mg per dose
- How often
- Twice daily in the trial
A frog-skin opioid many times stronger than morphine, best known from horse racing scandals.
- Dose
- Research only
- How often
- Varies
A Russian anti-anxiety dipeptide that blocks a panic receptor instead of sedating you.
- Dose
- 1 mg per day in the published human study
- How often
- Daily in the study
A neuroprotective molecule from a mouse screen. Never given to a person.
- Dose
- Research only
- How often
- No established pattern
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
No primary source has been traced for this compound yet. Treat everything on this page as unverified until one is. How we grade evidence
Beyond these, 186 records are indexed. Browse the records